Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 6;3(2):e000263.
doi: 10.1136/bmjgh-2016-000263. eCollection 2018.

Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India

Valerie Evans  1   2 , Peter Roderick  3 , Allyson M Pollock  3
Affiliations
Review

Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India

Valerie Evans et al. BMJ Glob Health. .

Abstract

There is growing national and international concern about the drug regulatory system in India. Parliamentary reports have highlighted the presence of high numbers of unapproved medicines and irrational combinations of both approved and unapproved drugs in the Indian market-place. Fixed-dose combinations (FDCs) are a peculiar feature of the Indian pharmaceutical landscape. Although metformin is a first-line treatment, FDCs for diabetes in India account for two-thirds of all diabetes medicine sales, and some have not been approved by the Central Drugs Standard Control Organization (CDSCO). This study examines the basis of efficacy and safety of top-selling metformin FDCs in India against four WHO criteria from clinical trials guidelines for the approval of FDCs. Data from a commercial drug sales database (PharmaTrac) were combined with searches through published literature, clinical trial registries, and published and unpublished trial websites of metformin FDCs in adults with type 2 diabetes mellitus. Five metformin FDCs in India from November 2011 to October 2012 accounted for 80% of all metformin FDC sales by value and volume. Although all five had obtained CDSCO approval, three had been sold and marketed prior to receiving this approval. Evaluation of published and unpublished clinical trials of these five FDCs found none provided robust evidence of safety and efficacy for the treatment of type 2 diabetes. Recommendations are made for publishing evidence that underpins drug approvals, marketing bans, greater transparency through updated clinical trials databases and legislative reform in order to prevent irrational FDCs from entering the market.

Keywords: India; diabetes mellitus type 2; metformin.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Timeline of important events concerning the five top-selling metformin fixed-dose combinations in India. CDSCO, Central Drugs Standard Control Organization; US FDA, US Food and Drug Administration.
See this image and copyright information in PMC

References

    1. U.S. Food and Drug Administation. Novel drug approvals. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/defau... (accessed 08 Jul 2016).
    1. Ministry of Health and Family Welfare, Department of Health and Family Welfare. Gazette of India, 10 March 2016. New Delhi, 2016. http://www.cdsco.nic.in/writereaddata/GSR705E.pdf (accessed 08 Jul 2016).
    1. McGettigan P, Mahajan R, Kadam A, et al. Regulatory upheaval and irrational medicines in India: a study of fixed dose combination drugs. PLoS Med 2015;12:e1001826. - PMC - PubMed
    1. Evans V, Pollock AM. The proliferation of irrational metformin fixed-dose combinations in India. Lancet Diabetes Endocrinol 2015;3:98–100. 10.1016/S2213-8587(14)70239-6 - DOI - PubMed
    1. Economic Times. 26 new drugs permitted for sale without trials in India. 18 August 2013. http://articles.economictimes.indiatimes.com/2013-08-18/news/41422720_1_... (accessed 08 Jul 2016).

LinkOut - more resources